Advances in protein subunit vaccines against tuberculosis

Area of Science:

• Infectious Diseases
• Vaccinology
• Biotechnology

Background:

• Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains a significant global health threat with high mortality.
• The current Bacille Calmette-Guérin (BCG) vaccine has limitations in protecting adults against TB.
• Protein subunit vaccines represent a promising alternative strategy for TB control.

Purpose of the Study:

• To review recent advancements in protein subunit vaccine research for tuberculosis.
• To highlight the potential of novel vaccine strategies in combating TB.
• To facilitate the optimization of protein subunit vaccines for TB eradication.

Main Methods:

• Leveraging bioinformatics and structural biology for Mtb antigen identification and optimization.
• Developing multistage subunit vaccines by fusing immunodominant antigens.
• Utilizing novel adjuvants to enhance vaccine immunogenicity.
• Employing advanced animal models for preclinical vaccine efficacy assessment.

Main Results:

• Protein subunit vaccines demonstrate potential for both preventing and treating TB.
• Multistage subunit vaccines are being developed by combining antigens from different infection stages.
• New adjuvants are improving the efficacy of subunit vaccines.
• Preclinical assessments using improved animal models are yielding more accurate protection data.

Conclusions:

• Protein subunit vaccines are a rapidly advancing field with significant potential to overcome the limitations of current TB vaccines.
• Continued research and development, particularly in antigen selection and adjuvant technology, are crucial for the successful eradication of TB.
• The integration of various scientific disciplines is accelerating the development of effective TB protein subunit vaccines.